Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

Massachusetts General Hospital

ClinicalTrials.gov lists Massachusetts General Hospital as lead sponsor of 2,574 trials. It has 885 active development programs and 484 approved assets.

US Hospital Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

190 0 1992 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 184 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 190 in 2026 and about 160 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 26 trials are registered to start in 2027 or later.

Logo Massachusetts General Hospital, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers Massachusetts General Hospital: 2,574 lead-sponsored trials and 1 legal-entity registration. Part of Mass General Brigham.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the Massachusetts General Hospital report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (855)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Trials by start year as sponsor or collaborator (34)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 26 trials are registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 184
2025 129
2024 138
2023 159
2022 126
2021 156
2020 151
2019 167
2018 157
2017 175

Prediction, not a registry value: median of 36 months from start to primary completion across 280 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 1,766 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (885)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Nivolumab Protocol Colorectal Neoplasms Phase 3 1
Nivolumab Protocol Colonic Neoplasms Phase 3 1
FOLFIRI Protocol Colonic Neoplasms Phase 3 1
FOLFIRI Protocol Colorectal Neoplasms Phase 3 1
Encorafenib/Binimetinib/Cetuximab Protocol Colonic Neoplasms Phase 3 1

Approved assets (484)

Shown in this order: max phase first.

Approved assets
Drug Trials
RITUXIMAB 17
(R,S)-ketamine (Pilot I) 14
D-Cycloserine 14
CARBOPLATIN 12
Escitalopram 11

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
39% hit target (n=855) 37% on time (n=839)

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
NAI 4

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
MASSACHUSETTS GENERAL HOSPITAL Boston, US FDA

CLIA clinical laboratory certificates (3)

Shown in this order: active first, then certificate type.

CLIA clinical laboratory certificates
Lab Certificate Status
MASSACHUSETTS GENERAL HOSPITAL Certificate of waiver Terminated
MASSACHUSETTS GENERAL HOSPITAL Certificate of waiver Terminated
MASSACHUSETTS GENERAL HOSPITAL Certificate of waiver Terminated

Biomarker capability evidence (4,206)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCB1 Trial sponsor Named in trial inclusion criteria
ABCB4 Trial sponsor Named in trial inclusion criteria
ABCD1 Trial sponsor Named in trial inclusion criteria
ABCG2 Trial sponsor Named in trial inclusion criteria
ABL1 Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.

Counted at group level under Mass General Brigham: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.